MS4A1 and B-cell non-Hodgkin lymphoma: Rituximab (MabThera, Rixathon, Truxima) is human/Murine, chimeric monoclonal IgG1 initially used exclusively in the treatment of non-Hodgkin B-cell lymphoma by binding to CD20 antigen which is upregulated in malignant B-cells.